Month: November 2022

On January 3, 2008, Tornero Montano, Jose Ruben; Quintana Hau, Juan De Dios; Baiza Duran, Leopoldo Martin; Rodriguez Franco, Norma Patricia; Gonzalez, Jaime R.; Jimenez Bayardo, Arturo published a patent.Formula: C17H21ClFN3O4 The title of the patent was An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride. And the patent contained the following:

The invention concerns a topically applied ophthalmic formulation in suspension which contains loteprednol etabonate and ciprofloxacin hydrochloride. Moreover, said formulation contains a polymer as a thickening agent which is derived from the acrylic acid known generically as Carbopol, a nonionic surfactant, an ionic tonicity agent and a nonionic tonicity agent, which are physico-chem. compatible, stable and appropriately dissolved in the suspension. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to loteprednol etabonate ciprofloxacin ophthalmic formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 11, 2006, Dillen, Kathleen; Vandervoort, Jo; Van den Mooter, Guy; Ludwig, Annick published an article.Electric Literature of 86393-32-0 The title of the article was Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. And the article contained the following:

The objective of present study was to prepare pos. charged ciprofloxacin-loaded nanoparticles providing a controlled release formulation. The particles were prepared by water-in-oil-in-water (w/o/w) emulsification and solvent evaporation, followed by high-pressure homogenization. Two non-biodegradable pos. charged polymers, Eudragit RS100 and RL100, and the biodegradable polymer poly(lactic-co-glycolic acid) or PLGA were used alone or in combination, with varying ratios. The formulations were evaluated in terms of particle size and zeta potential. Differential scanning calorimetry measurements were carried out on the nanoparticles and on the pure polymers Eudragit and PLGA. Drug loading and release properties of the nanoparticles were examined The antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus was determined During solvent evaporation, the size and zeta potential of the nanoparticles did not change significantly. The mean diameter was dependent on the presence of Eudragit and on the viscosity of the organic phase. The zeta potential of all Eudragit containing nanoparticles was pos. in ultrapure water (around +21/+25 mV). No burst effect but a prolonged drug release was observed from all formulations. The particles’ activity against P. aeruginosa and S. aureus was comparable with an equally concentrated ciprofloxacin solution The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to ciprofloxacin eudragit polylactide polyglycolide nanoparticle, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Martinez-Espinosa, Juan Carlos; Rodriguez-Villalon, Osvaldo; Cordova-Fraga, Teodoro; Perez-Careta, Eduardo; Guzman-Sepulveda, Jose Rafael; Madrid-Molina, Laura; Guzman-Cabrera, Rafael published an article in 2020, the title of the article was Quantitative pharmaceutical analysis based on the PCA of Raman spectra.Product Details of 86393-32-0 And the article contains the following content:

In the present work we examine the distribution of ciprofloxacin drug as an active ingredient in tablets samples from eight different laboratories Addnl., control samples with different concentration were prepared for calibration. Raman spectra were recorded from all samples, including controls, and a principal component anal. (PCA) was implemented on them. The results of the PCA on control samples show that a clear discrimination among the different samples can be achieved and, more importantly, that the principal component of the Raman spectra has a well-defined, linear relation with the concentration of ciprofloxacin. Such a strong, statistically significant linear correlation obtained for the control samples constitutes our calibration for the quant. anal. of com. pharmaceutical compounds The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to principal component analysis quant pharmaceutical raman spectrum, Organic Analytical Chemistry: Determinations and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 1998, Jorand-Lebrun, Catherine; Valognes, Delphine; Halazy, Serge published an article.COA of Formula: C7H13ClN2O The title of the article was Use of triphosgene for direct preparation of carbamoyl chlorides from tertiary benzylamines. And the article contained the following:

Treatment of tribenzylamine with triphosgene in CH2Cl2 gave dibenzylcarbamoyl chloride in 71% yield. Several other amines, e.g., I (X = CO, MeN), underwent similar reactions. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to triphosgene reaction tertiary amine, carbamoyl chloride preparation, General Organic Chemistry: Synthetic Methods and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 2013, Akbari, Vajihe; Abedi, Daryoush; Pardakhty, Abbas; Sadeghi-Aliabadi, Hojjat published an article.Synthetic Route of 86393-32-0 The title of the article was Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. And the article contained the following:

In order to propose non-ionic surfactant vesicles (niosomes) for the treatment of intracellular infections, a remote loading method (active drug encapsulation) followed by sonication was used to prepare nano-niosome formulations containing ciprofloxacin (CPFX). Size anal., size distribution and zeta potentials of niosomes were evaluated and then their antimicrobial activity, cellular uptake, cytotoxicity, intracellular distribution, and antibacterial activity against intracellular Staphylococcus aureus infection of murine macrophage-like, J774, cells were investigated in comparison to free drug. Our findings reveal that size and composition of the niosome formula can influence their in vitro biol. properties. Vesicles in the 300-600 nm size range were phagocytosed to a greater degree by macrophages in comparison to other size vesicles. The min. inhibitory concentrations (MICs) of CPFX-loaded niosomes were two to eightfold lower than MICs of free CPFX. In addition, niosome encapsulation of CPFX provided high intracellular antimicrobial activities while free CPFX is ineffective for eradicating intracellular forms of S. aureus. Encapsulation of CPFX in niosomes generally decreased its in vitro cytotoxicity. Our results show that niosomes are suitable drug delivery systems with good efficacy and safety properties to be proposed for drug targeting against intracellular infections. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to staphylococcus ciprofloxacin hydrochloride nanoniosome antimicrobial, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 3, 2003, Wall, Michael G.; Conroy, Peter J. published a patent.Application of 86393-32-0 The title of the patent was Method of treating middle ear infections. And the patent contained the following:

Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to eardrum perforation middle ear infection dexamethasone ciprofloxacin, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 14, 2018, Bittirov, A. M.; Kabardiev, S. Sh.; Begieva, S. A.; Kabardiev, Sh. S.; Bittirov, I. A.; Karpushchenko, K. A.; Bittirova, A. A. published a patent.Computed Properties of 86393-32-0 The title of the patent was Ointment type panpharmacon for complex treatment of animal eye diseases and method of producing thereof. And the patent contained the following:

This invention relates to the field of veterinary medicine and an ointment-type panpharmacon for the complex treatment of cattle thelaziosis, complicated by staphylococci, streptococci, chlamydia, Pseudomonas aeruginosa, Hemophilus spp., comprising ciprofloxacin hydrochloride monohydrate, and is characterized in that it contains micronized fenbendazole having a particle size of 25-50 μ, and as an ointment base – an alloy of petrolatum of “”eye ointments”” type and lanolin anhydrous, and a preservative – Nipasol, the components in the agent being in a certain ratio in mass %, per 100 g of ointment. The invention provides an expansion of the arsenal of means for local treatment of cattle thelaziosis, complicated by staphylococci, streptococci, chlamydia, Pseudomonas aeruginosa, Hemophilus spp. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to ointment eye thelaziosis bacterial infection anthelmintic bactericide, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2021, Han, Ling; Ma, Yingbo; Dou, Hao; Fan, Wei published an article.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the article was Dual-functional SFP/PAN based nano drug release system for treatment and nutrients. And the article contained the following:

Nano drug delivery systems can control the ordered release of drugs. To achieve the target of supplying therapeutics and nutrients at the same time, a novel nano drug delivery system with a core-shell structure was prepared by coaxial electrospinning. Polyacrylonitrile (PAN) has been used to produce a drug release scaffold in the shell section, mixed with absorbable silk fibroin peptide (SFP) as a nutrient. Ciprofloxacin (CPFX), a broad-spectrum antibiotic, was used as the core, as well as an antibacterial agent. Owing to its low mol. weight, using a pure SFP thin solution to manufacture nanofibers by electrospinning is still tech. challenging. Thus, different ratios of PAN to SFP were used in the shell electrospinning solution In this research, a novel nano dual-functionality drug delivery system has been successfully prepared In vitro testing demonstrated that nanofibers could supply more nutrients with increasing SFP in shell solutions; however, the ability to maintain controlled release was reduced. It was found that the nanofiber membrane had the best controlled drug release capability for a PAN-to-SFP mass ratio of 95:5. Overall, most ciprofloxacin was released in the first 12 h, while the release of SFP was constant throughout the first 24 h. Our modeling demonstrated that the release of CPFX and SFP is best described using a first-order kinetic model. The developed drug delivery system is designed to release antimicrobial drugs in a controlled manner and provide absorbable nutrients simultaneously. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to silk fibroin peptide polyacrylonitrile nutrient nano drug release system, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Han, Yue; Bai, Can; He, Xi-Meng; Ren, Qing-Ling published an article in , the title of the article was P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.HPLC of Formula: 1428327-31-4 And the article contains the following content:

Atractylenolide I (Atr-I) was found to sensitize a variety of human cancer cells in previous studies. Purinergic P2X7R plays important role in different cancers. However, whether Atr-I could generate antitumor activity in human cervical cancer cells and P2X7R get involved in this effect remain unclear. In this study, Hela (HPV 18 +) and SiHa (HPV 16 +) cells were treated with different doses of Atr-I. The results indicated that agonist and antagonist of P2X7 receptors, BzATP and JNJ-47965567 (JNJ), could suppress the proliferation of Hela and SiHa cells. Atr-I demonstrated a considerable antitumor effect in both human cervical cancer cells in vitro. Atr-I combined with P2X7R agonist, BzATP, restored Atr-I-induced growth inhibition in Hela cells but not in SiHa cells. However, the combinatorial treatment of P2X7R antagonist JNJ and Atr-I has an additive effect on cell growth inhibition in SiHa cells rather than in Hela cells. It implied that P2X7R would get involved in the anti-human cervical cancer cells effect of Atr-I. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).HPLC of Formula: 1428327-31-4

The Article related to atractylenolide anticancer agent p2x7 receptor cervical cancer, atractylenolide i, hela cells, human cervical cancer cells, p2x7rs, siha cells, Placeholder for records without volume info and other aspects.HPLC of Formula: 1428327-31-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Saussele, Susanne; Kohlbrenner, Katharina; Vogelmann, Tobias; Schubert, Tino published an article in 2022, the title of the article was Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis.COA of Formula: C26H29Cl2N5O3 And the article contains the following content:

Real-world data on usage of 1st-, 2nd-, and 3rd-generation tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) are scarce. This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML. This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (n = 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence, and therapy distribution were performed descriptively. 151 Patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95% confidence interval [CI]: 1.34-2.20) and a prevalence of 14.9 (95% CI: 13.70-16.03) per 100,000 inhabitants. For the incidence cohort, data on 1st-line therapy were available for 124 patients and distributed across imatinib (N = 52), nilotinib (N = 44), dasatinib (N = 12), chemotherapies as hydroxycarbamide (N = 11), and ponatinib/bosutinib (N = 5). Twenty-six percent of patients switched TKI therapy at least once in 3 years. In the prevalence cohort, 423 patients (66.5%) had claims on existing or newly emerged cardiovascular diseases (CDs). No significant differences (p = 0.32) between TKIs in patients with CD were found. Every fourth patient switched TKI therapy within the first 3 years after treatment initiation. Switches were more likely when hints of disease progression or intolerability were observable in the database. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to human disease progression chronic myeloid leukemia, chronic myeloid leukemia, chronic myeloid leukemia, claims data analysis, real-world evidence, tki, Placeholder for records without volume info and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics